

The Companies Officer  
ASX Limited  
Level 40, Central Park  
152-158 St Georges Terrace  
PERTH WA 6000

## Notice under ASX Listing Rule 3.10.5A

Recce Pharmaceuticals Ltd (**ASX:RCE**) (**Company**) issued 5,742,590 fully paid ordinary shares under ASX Listing Rule 7.1A, as detailed in the Appendix 3B released to the ASX on 15 February 2019. The shares were issued as part of the Placement which the Company completed raising \$1.8 million (before costs).

In accordance with ASX Listing Rule 3.10.5A, the Company confirms the following details:

1. The dilution caused to the existing shareholders of the Company from the issue of shares under ASX Listing Rule 7.1A is 5.36%.
2. The shares were issued for cash consideration and as part of the Company's Placement which raised \$1.8 million (before costs). The Company considered the Placement, compared to other types of capital raising (where existing ordinary shareholders would have been eligible to participate), was the most efficient and expedient method of raising funds. If the Company conducts a further capital raising in the future, it will continue to consider all options, including those where existing ordinary shareholders would have been eligible to participate.
3. No underwriting agreements were entered into with respect to the Placement.
4. The Company has agreed to pay a total fee equivalent to 6% of the funds raised under the Placement, in addition to the issue of 1,800,000 unlisted options to DJ Carmichael as announced to ASX on 8 February 2019.

For more information, please contact the undersigned on (+61) 2 8072 1400.



Alistair McKeough  
Company Secretary

---

For further information please visit [www.recce.com.au](http://www.recce.com.au) or contact:

### Investor Relations

James Graham  
Executive Director  
Recce Pharmaceuticals Ltd  
Tel: +61 (02) 8075 4585

### Media (Australia)

Andrew Geddes  
CityPR  
Tel: +61 (02) 9267 4511

### Media (International)

Sue Charles/Gemma Harris  
Instinctif Partners  
Tel: +44 (0)20 7866 7860  
E: [recce@instinctif.com](mailto:recce@instinctif.com)



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA